In one of the largest licensing deals in the Australian biotechnology industry, Dimerix (ASX:DXB) has signed an exclusive US licence agreement with Amicus Therapeutics to commercialise its kidney disease drug candidate DMX-200. …
Dimerix secures one of the largest licensing deals in Australian biotechnology
May 1, 2025 Australian Biotech
Latest Video
New Stories
-
Arrotex bets on Recce's Phase 3 gel as diabetic foot infections get harder to treat
October 23, 2026 - - Latest News -
The imperative is to negotiate with the fifth year of the agreement in mind
October 23, 2026 - - Latest News -
The private medicines boom has mostly passed vaccines by, for now
October 23, 2026 - - Latest News -
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News -
Quarterly update shows Telix holds course for a US$1 billion milestone year
October 21, 2026 - - Latest News